Pantoavenir IV

/ BioAvenir

Duodenal ulcer, gastric ulcer, moderate and severe reflux esophagitis: The recommended intravenous dosage is one vial (40 mg pantoprazole) PantoAvenir I.V. per day.
Long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions: Patients should start the treatment with a daily dose of 80 mg PantoAvenir I.V. Thereafter, the dosage
can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily.
A temporary increase of the dosage above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.
In case a rapid acid control is required, a starting dose of 2 x 80 mg PantoAvenir I.V. is sufficient to manage a decrease of acid output into the target range (<10 mEq/h) within one hour in the majority of patients.
The intravenous formula must be replaced by the oral formula as soon as it is clinically justified.
General instructions: A ready-to-use solution is prepared by injecting 10 ml of physiological sodium chloride solution into the vial containing the dry substance. This solution may be administered directly or may be administered after mixing with 100 ml physiological sodium chloride solution, or 5% Glucose.
PantoAvenir I.V. should not be prepared or mixed with solvents other than those specified.
After preparation the solution must be used within 12 h.
The drug should be administered intravenously over 2 – 15 minutes.
As soon as oral therapy is possible, treatment with PantoAvenir I.V. should be discontinued and 40 mg Pantoprazole p.o. should be administered instead.

Duodenal ulcer, gastric ulcer, moderate and severe reflux esophagitis, Zollinger-Ellison Syndrome and other pathological hypersecretory conditions.

Known hypersensitivity. Should not be co-administered with atazanavir.

The I.V. administration of pantoprazole is recommended only if oral application is not appropriate. Not indicated for mild GI complaints such as nervous dyspepsia. The reflux esophagitis diagnosis must be confirmed by means of endoscopy. In the presence of any alarm symptom (e.g., significant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis, anemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with pantoprazole may alleviate symptoms and delay diagnosis.Further investigation is to be considered if symptoms persist despite adequate treatment.Several published studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established guidelines.Elderly patients and impaired renal function: Daily dose of 40 mg should not be exceeded. Severe liver impairment: Daily dose should be reduced to 20 mg. Liver enzymes should be monitored during therapy. In case of a rise in the liver enzymes, treatment should be discontinued.
See literature for full details.

See literature for full details.

Atazanavir.